CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 97 enrolled
Drug / intervention
Lamotriginedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00579982
NCT00579982Phase 3Completed

An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects With a Mood Disorder

GlaxoSmithKline·interventional·Posted Dec 24, 2007·Updated Dec 16, 2016

In Brief

A Phase 3 clinical trial evaluating Lamotrigine for Mood Disorders. Completed, enrolled 97 participants across 18 sites.

Detailed Summary

To determine the convenience and satisfaction of new orally disintegrating tablet formulation (ODT) of lamictal in subjects with a mood disorder. This was a multicenter, open-label study in participants with a mood disorder, who reported difficulty or discomfort in swallowing the currently marketed IR compressed tablet formulation of lamotrigine and who had a person (such as a spouse, partner, companion, aid, nurse, caregiver, etc) willing to complete a Companion/Caregiver Question. Subjects were switched from the currently marketed lamotrigine IR formulation to a matching dose of lamotrigine IR orally disintegrating tablet (ODT) for 3 weeks to determine convenience and satisfaction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMood Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 24, 2007
Enrollment StartJan 1, 2008
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 18.5 years ago

Interventions

Lamotriginedrug

Experimental formulation